23andme, Inc.

Alector LLC

Samuel Nalle

Chingwei Vivian Lee

Krista Maureen McCutcheon

Yu Chen

Shouhua Xiao

Germaine Fuh-Kelly

Yao-ming Huang

Louise Scharf

Tina Thai

Zuoan Yi

Valentine Yeung

Augusta Eleanor Broughton

Navneet Singh

Jeonghoon Sun

Spencer Liang

Hua Long

Rashmi Bankoti

The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD96 receptor protein (hu-CD96) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD96. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD96 binding to CD155, including effects arising from CD96 interactions with CD226 and/or TIGIT.

Anti-CD96 antibodies and methods of use thereof

The present disclosure is generally directed to Siglec-9 ECDs and Siglec-9 ECD fusion molecules, and methods of treatment using Siglec-9 ECDs and Siglec-9 ECD fusion molecules.

Siglec-9 ECD fusion molecules

Growing community of inventors

Pacifica, CA, United States of America

Samuel Nalle